Sodium Lactate Solution
OtherInfusion of sodium-lactate solution
NCT Number: NCT06665763
The aim of the proposed study is to investigate the effect of increased plasma lactate concentrations on the heart and brain's metabolism of other energy sources, primarily glucose in the brain and glucose and FFA in the heart.
The investigator hypothesize that:
* An acute increase in lactate plasma concentration will decrease cerebral glucose uptake and increase cerebral blood flow * An acute increase in lactate plasma concentration will decrease palmitate and glucose uptake in the myocardium, and increase myocardial perfusion
Trial opening soon.
Get Notified55 year–75 year
All sexes
Interventional
Not applicable
Department of Nuclear Medicine & PET-Centre, Aarhus, N, Denmark
SCREENING VISIT
During the initial screening visit, the investigators will inform all potential volunteers about the project, and volunteers will have the chance to ask questions about participation in the project.
The investigators will register the following data
After assessment of inclusion- and exclusion criteria remaining volunteers will be offered to participate in the project. The investigators will screen potential volunteers with the following blood samples: haemoglobin, HbA1c, glucose, cholesterol, triglyceride, TSH, creatinine, albumin, sodium, potassium, ALAT, ASAT, bilirubin and coagulation parameters.
Blood samples and randomization will not take place until volunteers have signed the informed consent form.
MAGNETIC RESONANCE IMAGING (MRI) SCAN
The investigators will perform a cerebral MRI for the purpose of anatomical localisation for alignment with the PET scans on the 1st and 2nd study day.
1st STUDY DAY:
The volunteers will arrive fasted (8 hours) at the Department of Nuclear Medicine & PET-Centre at 7.30 a.m., where the subject will have an arterial catheter placed for arterial blood sampling during PET scans as well as two venous catheters for blood sampling and continued administration of intravenous fluids (saline or Na-lactate) and adenosine. At 9.00 a.m., we will start the Na-lactate or saline infusion.
From 9.30 a.m., the investigators will perform PET scans with administration of relevant PET tracers preceding each scan. The investigators will perform PET scans in the following order:
Following the [11C]Acetate scan the investigators will administrate a continued infusion of insulin (0,3 mIE/kg/min) and 20% glucose throughout the rest of the study day in order to achieve hyperinsulinemic-euglycemic conditions (clamp conditions). To correct for attenuation, we will perform three lowdose, non-contrast enhanced CT scans over the course of the study day. The investigators will draw blood samples every hour.
2nd STUDY DAY
The PET scan regime during the 2nd study day is identical to the 1st study day. If volunteers were administered Na-lactate during the 1st study day they will be administered saline during the 2nd studyday and vice versa.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Infusion of sodium-lactate solution
NaCl solution
Other names: NaCl
Time frame: From T=300-360 (minutes)
Cerebral glucose uptake ([18F]FDG PET scan) under basal and hyperinsulinemic- euglycemic conditions (clamp conditions).
Time frame: T = 0-10 (minutes)
Cerebral blood flow ([15O]H2O PET scan)
Time frame: T = 0-10 (minutes)
Myocardial perfusion ([15O]H2O PET scan)
Time frame: T = 300-360 (minutes)
Myocardial glucose uptake ([18F]FDG PET scan)
Time frame: T = 30-70 (minutes)
Myocardial FFA uptake and oxidation ([11C]Palmitate PET scan)
Time frame: T=0-10 (minutes)
Myocardial contractility (ejection fraction based on ECG-gated PET scan)
Time frame: T=150-180 (minutes)
Myocardial oxygen consumption and efficiency ([11C]Acetate PET scan)
Time frame: T = -60 to 360 (minutes)
A number of cardiometabolic blood samples will be collected during the whole study day.
Contact information is provided by the study sponsor or research team.
Esben Søndergaard, MD, PhD
CONTACT
Jens Voigt, MD
CONTACT
University of Aarhus
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04710875
Healthy, Hyperlactatemia
Aarhus, Central Region Denmark, Denmark
View Trial DetailsNCT04299815
Glucose Metabolism Disorders, Healthy
Aarhus, Denmark
View Trial DetailsNCT07737496
Healthy
Changsha, Hunan, China
View Trial DetailsNCT07727785
Healthy
Biberach, Germany
View Trial Details